ICU Medical (ICUI) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue reached $589.1M, up 6.5% year-over-year, with gross profit rising to $204.9M and adjusted EBITDA at $94.8M.

• Net loss for Q3 2024 was $(33.0)M, compared to net income of $7.2M in Q3 2023; adjusted diluted EPS was $1.59.

• Announced a strategic joint venture with Otsuka for IV solutions, including a $200M upfront payment and future deconsolidation of ~$350M revenue and ~$25M adjusted EBITDA.

• Gross margins improved to 34.8% in Q3 2024, exceeding expectations due to supply chain efficiencies, FX, and favorable sales mix.

• Free cash flow generation was strong, increasing the cash balance to $312.5M at quarter-end.

Financial highlights

• Q3 2024 revenue: $589.1M (+6.5% YoY); Consumables segment grew 9–9.5% YoY; Infusion Systems up 7–7.2% YoY; Vital Care flat to +1.4% YoY.

• Adjusted EBITDA for Q3 was $94.8M, up 6% YoY; adjusted gross margin was 37%.

• Free cash flow for Q3 was $16.2M; year-to-date free cash flow reached $109.2M.

• Ended Q3 with $1.6B debt and $312.5M cash.

• SG&A expenses were $162.7M in Q3 2024; R&D expenses were $21.0M.

Outlook and guidance

• Adjusted EBITDA guidance raised to $355–$365M; adjusted EPS guidance increased to $5.40–$5.70.

• FY 2024 GAAP net loss guidance widened to $(130)M–$(122)M; GAAP diluted loss per share guidance updated to $(5.28)–$(4.98).

• Q4 gross margin expected at 36–37% due to higher IV solutions mix and FX headwinds.

• Transaction with Otsuka expected to be EPS neutral in 2025 and to accelerate new product development.